<DOC>
	<DOCNO>NCT01489319</DOCNO>
	<brief_summary>The purpose study determine relationship lipid-induced inflammation ovarian androgen secretion woman polycystic ovary syndrome ( PCOS ) ; examine effect salsalate polygonum cuspidatum extract ( PCE ) contain resveratrol lipid-induced inflammation , ovarian androgen secretion , body composition ovulation subset normal weight woman PCOS .</brief_summary>
	<brief_title>Evaluation Oral Lipid Ingestion Relation Ovarian Androgen Secretion Polycystic Ovary Syndrome ( PCOS )</brief_title>
	<detailed_description>The investigator hypothesize woman PCOS , HCG administration stimulate exaggerate ovarian androgen response , dairy cream ingestion stimulate white blood cell generate inflammatory response , relationship HCG-stimulated ovarian androgen secretion inflammatory response dairy cream ingestion regardless body fat status . Thirty ( 30 ) woman PCOS ( 10 normal weight normal abdominal adiposity , 10 normal weight increase abdominal adiposity 10 obese ) 30 ovulatory control woman ( 10 normal weight normal abdominal adiposity , 10 normal weight increase abdominal adiposity 10 obese ) participate 3-year period . The investigator also hypothesize salsalate PCE administration 12 week attenuate ovarian androgen response HCG administration inflammatory response dairy cream ingestion , reduce abdominal adiposity , increase insulin sensitivity induce ovulation normal weight woman PCOS . A subset 16 woman PCOS 8 receive salsalate ( 4 normal weight normal abdominal adiposity 4 normal weight increase abdominal adiposity ) 8 receive PCE ( 4 normal weight normal abdominal adiposity 4 normal weight increase abdominal adiposity ) participate intervention 3-year period . This pilot project help determine feasibility conduct large double-blind , randomize trial woman PCOS test latter hypothesis .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Salicylsalicylic acid</mesh_term>
	<mesh_term>Sodium Salicylate</mesh_term>
	<criteria>General Acceptable health base interview , medical history , physical examination , lab test Ability comply requirement study Ability willingness provide sign , witness informed consent Inclusion Criteria PCOS : Between age 1840 year Body mass index 18 25 , 30 40 Less equal 8 period annually An elevated serum androgen level skin manifestation androgen excess Normal thyroid function test normal prolactin level Exclusion lateonset adrenal hyperplasia Inclusion Criteria Ovulatory Controls : Between age 1840 year Body mass index 18 25 , 30 40 Normal regular monthly period No clinical evidence androgen excess No evidence polycystic ovary ultrasound Diabetes mellitus Clinically significant pulmonary , cardiac , renal , hepatic , neurologic , psychiatric , infectious , malignant disease High blood pressure Current recent ( within 6 week prior study entry ) injection drug know suspected affect reproductive function include oral contraceptive , metformin , thiazolidinediones , glucocorticoid , GnRHagonists , antiandrogens ( spironolactone , flutamide , etc ) Documented suspected history use recent ( within one year ) illicit drug abuse alcoholism Tobacco smoking salsalate PCE administer Ingestion investigational drug within 4 week prior study onset Pregnancy lactation ( less equal 6 week postpartum )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>inflammation</keyword>
	<keyword>body composition</keyword>
	<keyword>hyperandrogenism</keyword>
	<keyword>insulin resistance</keyword>
</DOC>